- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03506048
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the efficacy of lenvatinib pretreatment along with radioactive iodine (RAI) in patients with previously treated RAI sensitive thyroid cancer.
SECONDARY OBJECTIVES:
I. To demonstrate the safety of the combination of lenvatinib and RAI in patients with Iodine sensitive differentiated thyroid carcinoma (DTC).
II. To assess dynamic changes in established serum based biomarkers of DTC (thyroglobulin [Tg] and Tg antibody).
III. To explore the utility of protein and genetic biomarkers to predict treatment efficacy.
OUTLINE:
Patients receive lenvatinib orally (PO) once daily (QD) for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive iodine I-131 PO daily as standard of care.
After completion of study treatment, patients are followed up within 6 weeks, every 3 months for 1 year, and then periodically thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prior treatment with therapeutic dose of radioactive iodine (> 50 mCi) with evidence of RAI uptake on delayed scan and with progression (biochemical or anatomic) within 12 months of RAI
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky ≥ 80%)
- Leukocytes ≥ 3,000/µL
- Absolute neutrophil count ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x institutional upper limit of normal
- Creatinine within normal institutional limits OR
- Creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal
- Confirmed diagnosis of differentiated thyroid cancer (follicular or papillary thyroid cancer and their variants)
- Ability and willingness to use appropriate contraception; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 2 weeks after completion of lenvatinib administration
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) by chest x-ray or as ≥ 10 mm (≥ 1 cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have received RAI within 12 weeks of planned retreatment
- Prior receipt of cumulative RAI doses in excess of 1000 mCi
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1)
- Patients who are receiving any other investigational agents
- Patients with previously untreated and or symptomatic brain metastases are excluded from this clinical trial because of the risk of intracranial bleeding with angiogenic agents and tumoral swelling from RAI
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenvatinib
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with uncontrolled hypertension (requirement for more than 2 blood pressure [BP] medications or grade 2 or higher BP elevation while on adequate doses of not more than 2 antihypertensive agents) are excluded from the study because one of the significant adverse events of lenvatinib is worsening hypertension
- Fridericia's corrected QT (QTcF) interval prolongation greater than 500 ms
- Recent arterial thromboembolic event within the previous 6 months
- Urine dipstick proteinuria ≥ 2+ or nephrotic range proteinuria on ≥ 2 gram in 24-hour urine
- History of gastrointestinal perforation, abscess or fistula
- History of and or medical condition (e.g. diverticular disease; aneurysm) that predisposes to risk of major hemorrhage
- Pregnant women are excluded from this study because lenvatinib is a tyrosine kinase inhibitor agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lenvatinib, breastfeeding should be discontinued if the mother is treated with lenvatinib
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with lenvatinib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (lenvatinib)
Patients receive lenvatinib PO QD for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity.
Patients also receive radioactive iodine (RAI) I-131 orally as standard of care.
|
Given orally once daily continuously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time To Progression
Time Frame: Up to 2 years from when a participant started at baseline
|
The time-to-progression (TTP) will be the primary endpoint for study, and will be determined using all enrolled patients in accordance with the intention to treat (ITT) principle.
The study is formulated to have power = 0.90 at the significance level of 0.05 to correctly detect that improvement in median time to progression from 6 moths to 12 months.
|
Up to 2 years from when a participant started at baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Objective Response
Time Frame: Up to 2 years from when a participant started at baseline
|
Objective response rate and disease control rate will be summarized. For the expansion cohorts, objective response rate will be presented along with 95% exact confidence intervals. Patients will be assigned one of the following categories: complete response (CR), partial response (PR), stable disease (SD), progressive disease, non-evaluable, and disease control (CR + PR + SD). The same method of assessment and the same technique will be used to characterize each identified and reported lesion at baseline and during follow-up. |
Up to 2 years from when a participant started at baseline
|
Change in Thyroglobulin Levels
Time Frame: Up to 2 years from when a participant started at baseline
|
Biochemical response will be assessed using suppressed and stimulated thyroglobulin.
Thyroglobulin will be checked at baseline and post RAI every 3 months for 12 months and every 4-6 months thereafter as clinically indicated.
Stimulated thyroglobulin obtained at baseline, prior to RAI, at 3 months, 6 months and 12 months post RAI will be used to define biochemical response.
Unstimualte Tg levels may be used if unable to obtain stimulated Tg
|
Up to 2 years from when a participant started at baseline
|
Change in Thyroglobulin Antibody Levels
Time Frame: Up to 2 years from when a participant started at baseline
|
Biochemical response will be assessed using suppressed and stimulated thyroglobulin antibody.
Thyroglobulin antibody will be checked at baseline and post RAI every 3 months for 12 months and every 4-6 months thereafter as clinically indicated.
Stimulated thyroglobulin obtained at baseline, prior to RAI, at 3 months, 6 months and 12 months post RAI will be used to define biochemical response.
Unstimualte Tg levels may be used if unable to obtain stimulated Tg
|
Up to 2 years from when a participant started at baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Taofeek K. Owonikoko, MD, PhD, Emory University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Adenocarcinoma, Papillary
- Carcinoma
- Thyroid Diseases
- Thyroid Neoplasms
- Thyroid Cancer, Papillary
- Adenocarcinoma, Follicular
- Carcinoma, Papillary
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Lenvatinib
Other Study ID Numbers
- IRB00101617
- NCI-2018-00144 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- Winship4271-18 (OTHER: Emory University Hospital/Winship Cancer Institute)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Differentiated Thyroid Gland Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedPoorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditionsUnited States
-
Providence Health & ServicesRecruitingBRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...United States
-
National Cancer Institute (NCI)Active, not recruitingPoorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditionsUnited States, Taiwan, Australia, Singapore, China
-
Beijing Scitech-Mq Pharmaceuticals LimitedRecruitingDifferentiated Thyroid CarcinomaChina
-
National Cancer Institute (NCI)TerminatedThyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid CancerUnited States
-
Saint Petersburg State University, RussiaWithdrawnPoorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 StageRussian Federation
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPoorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8United States
-
Peking University Cancer Hospital & InstituteCompletedDifferentiated Thyroid Carcinoma (DTC)
Clinical Trials on Lenvatinib
-
Memorial Sloan Kettering Cancer CenterCompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Fudan UniversityActive, not recruitingHepatocellular CarcinomaChina
-
Regina Elena Cancer InstituteUniversity of Pisa; University of Roma La Sapienza; University of Turin, Italy; Istituto Oncologico Veneto IRCCS and other collaboratorsRecruitingDifferentiated Thyroid Cancer | GenderItaly
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)Italy, Poland, Singapore, United States, China, Ukraine
-
Shandong New Time Pharmaceutical Co., LTDRecruitingHepatocellular CarcinomaChina
-
Cancer Institute and Hospital, Chinese Academy...Active, not recruitingHepatocellular Carcinoma | Radiotherapy | LenvatinibChina
-
CStone PharmaceuticalsActive, not recruitingHepatocellular CarcinomaSpain, China, United States, Poland, Italy, Taiwan
-
Eisai Inc.Merck Sharp & Dohme LLCCompletedSolid TumorsUnited States, China, Belgium, Australia, Italy, Korea, Republic of, Germany, Netherlands, Poland, Romania, Thailand
-
Eisai Inc.CompletedThyroid CancerUnited States, Australia, France, Poland, United Kingdom, Italy
-
Shanghai Zhongshan HospitalActive, not recruitingCholangiocarcinoma, IntrahepaticChina